Journal article

The Impact of Smoking in Adolescence on Early Adult Anxiety Symptoms and the Relationship between Infant Vulnerability Factors for Anxiety and Early Adult Anxiety Symptoms: The TOPP Study

Steven Moylan, Kristin Gustavson, Evalill Karevold, Simon Overland, Felice N Jacka, Julie A Pasco, Michael Berk

PLoS One | PUBLIC LIBRARY SCIENCE | Published : 2013

Grants

Awarded by National Health and Medical Research Council (NHMRC) Training Fellowship


Funding Acknowledgements

The TOPP study has been supported by grants from The Norwegian Research Council and The Norwegian Council for Mental Health. No specific funding was allocated for this analysis.Dr Moylan, Dr Gustavson, A/Prof Karevold, Prof Overland declare no conflicts of interests regarding this work. A/Prof Jacka has received grant/research support from the Brain and Behaviour Research Institute, the National Health and Medical Research Council, Australian Rotary Health, the Geelong Medical Research Foundation, the Ian Potter Foundation, Eli Lilly and The University of Melbourne and has been a paid speaker for Sanofi-Synthelabo, Janssen Cilag and Eli Lilly. She is supported by an National Health and Medical Research Council (NHMRC) Training Fellowship (#628912). A/Prof Pasco has received speaker fees from Amgen, Eli Lilly and Sanofi-Aventis and funding from the Geelong Region Medical Research Foundation, Barwon Health, Perpetual Trustees, the Dairy Research and Development Corporation, The University of Melbourne, the Ronald Geoffrey Arnott Foundation, ANZ Charitable Trust, the American Society for Bone and Mineral Research, Amgen (Europe) GmBH and the NHMRC. Prof Berk has received grant/research support from the National Institutes of Health (NIH), Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma and Servier, has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvayand Wyeth, and served as a consultant to Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck and Servier. The authors wish to state that these competing interests do not alter their adherence to all the PLOS ONE policies on sharing data and materials.